Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Plummer

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 5, 2020
Chemical sympathectomy reduces peripheral inflammatory responses to acute and chronic sleep fragmentationIla Mishra, Keelee B Pullum, Domnique C Thayer, et al.
Journal of Medical Entomology|December 21, 2004
An in vitro larval immersion microassay for identifying and characterizing candidate acaricidesW Hunter White, Philip R Plummer, Connie J Kemper, et al.
Cancer Research|October 16, 2012
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survivalAsima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignanciesH-T Arkenau, R Plummer, L R Molife, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumorsD Mahadevan, R Plummer, M S Squires, et al.
Developmental Neurobiology|September 25, 2008
Functional differentiation of a clone resembling embryonic cortical interneuron progenitorsHedong Li, Yu R Han, Caixia Bi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumoursJ Spicer, R Baird, A Suder, et al.
Journal of Cancer Research and Clinical Oncology|September 13, 2023
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial FindersS Rae, E Plummer, L Fitzgerald, et al.
Journal of the National Cancer Institute|December 25, 2010
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2Yvette Drew, Evan A Mulligan, Wan-Tse Vong, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 5, 2020
Chemical sympathectomy reduces peripheral inflammatory responses to acute and chronic sleep fragmentationIla Mishra, Keelee B Pullum, Domnique C Thayer, et al.
Journal of Medical Entomology|December 21, 2004
An in vitro larval immersion microassay for identifying and characterizing candidate acaricidesW Hunter White, Philip R Plummer, Connie J Kemper, et al.
Cancer Research|October 16, 2012
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survivalAsima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignanciesH-T Arkenau, R Plummer, L R Molife, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumorsD Mahadevan, R Plummer, M S Squires, et al.
Developmental Neurobiology|September 25, 2008
Functional differentiation of a clone resembling embryonic cortical interneuron progenitorsHedong Li, Yu R Han, Caixia Bi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumoursJ Spicer, R Baird, A Suder, et al.
Journal of Cancer Research and Clinical Oncology|September 13, 2023
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial FindersS Rae, E Plummer, L Fitzgerald, et al.
Journal of the National Cancer Institute|December 25, 2010
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2Yvette Drew, Evan A Mulligan, Wan-Tse Vong, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
Pageof 15